Paradigm Biopharmaceuticals Limited (ASX:PAR) is an ASX-listed biotechnology company focused on repurposing Pentosan Polysulfate Sodium (PPS), an FDA approved drug that has a long track record of safely treating inflammation over 60 years. The Company’s primary focus is on repurposing PPS (under the name ZILOSUL®) to treat Osteoarthritis (OA) – a market with over 31m sufferers in the USA alone.
More details about our programme can be found here.
Current shareholders click here to access and update your personal details.
17 April 2019 – Accelerated non-renounceable rights issue offer
Please access this booklet for all information and instruction relevant to the offer open to current shareholders, including: details and terms of the offer; action required; dates and deadlines; forms; and contact information.
If you have any queries concerning your entitlement please contact the company’s share registry on 1300 850 505 (within Australia) or +61 3 9415 4000 (outside Australia).